HYNES CONVENTION CENTER

Boston, Massachusetts
March 8–11, 2020

 

Conference Dates and Location: 
March 4–7, 2019 | Seattle, Washington
Abstract Number: 
41

MATERNAL HBV VIREMIA IS ASSOCIATED WITH ADVERSE INFANT OUTCOMES IN HIV/HBV WOMEN

Author(s): 

Debika Bhattacharya1, Rong Guo1, Chi-hong Tseng1, Lynda Emel2, Ren Sun1, Shih-Hsin Chiu1, Lynda Stranix-Chibanda3, Tsungai Chipato3, Neaka Z. Mohtashemi1, Kenneth Kintu4, Karim P. Manji5, Dhayendre Moodley6, Chloe Thio7, Yvonne Maldonado8, Judith S. Currier1

1University of California Los Angeles, Los Angeles, CA, USA,2Fred Hutchinson Cancer Research Center, Seattle, WA, USA,3University of Zimbabwe, Harare, Zimbabwe,4Makerere University–Johns Hopkins University Research Collaboration, Kampala, Uganda,5Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania, United Republic of,6University of KwaZulu-Natal, Durban, South Africa,7Johns Hopkins University School of Medicine, Baltimore, MD,8Stanford University, Stanford, CA, USA

Abstract Body: 

HIV/HBV coinfection is common, yet there is little information on maternal and infant clinical outcomes. We assessed the prevalence of HBV coinfection and its impact on HIV transmission and infant and maternal outcomes in HPTN 046, a HIV mother-to-child (MTCT) transmission study.

 

HPTN 046 was a randomized controlled clinical trial of HIV MTCT which evaluated 6 months of infant nevirapine vs placebo for HIV prevention. Mother-infant pairs were enrolled in sub-Saharan Africa from 2007-2010; 1579 women (78%) also received ART. Maternal samples were retrospectively tested for hepatitis B surface antigen (HBsAg), and if positive, were tested for hepatitis B e antigen (HBeAg) at study entry and HBV viral load (VL) at delivery. Women who were HBsAg positive were classified as HIV-HBV co-infected (HIV-HBV). High HBV VL was defined as >10[sup]6[/sup] IU/ml. The impact of HIV/HBV coinfection on HIV MTCT, low birth weight (LBW), infant mortality and maternal premature rupture of membranes and C-section was assessed using multivariate (MV) logistic and Cox regression.

 

Among 2025 HIV-infected (HIV) women, 88 (4.3%) were HIV-HBV. HIV-HBV women with high HBV VL had lower median CD4 T-cell count at study entry, when compared to HIV+/HBV- women or HIV-HBV women with HBV VL < 106 IU/ml (320, 490, and 434 cells/mm³, respectively (p<0.007)). In MV analysis, adjusted for maternal CD4, age, and maternal ART, infants born to women with high HBV VL were more likely to be low birth weight (LBW), compared to HIV+/HBV- and HBV low VL women: [30% (3/10) vs 10% (194/1953) vs 6% (5/78), respectively, p=0.03)]. In a dose response analysis, HBV VL greater than 102 IU/ML was associated with LBW [RR=6.1 (95% CI 1.31 - 28.39)]. HIV MTCT occurred in 2/10, 0/78, and 53/1953 high HBV VL, low HBV VL, and HIV+/HBV – women, respectively. High HBV VL was associated with HIV MTCT [(HR 6.75 (95% CI 1.86 – 24.50)]. There was no impact on infant mortality or maternal outcomes at 18 months.

 

In HIV/HBV coinfected women, HBV replication increases the risk for poor infant outcomes including LBW and potentially HIV MTCT. Reduction of antepartum HBV viremia may have beneficial effects beyond the prevention of HBV MTCT in HIV/HBV coinfection.

 

Session Number: 
O-04
Session Title: 
CRITICAL ISSUES IN MATERNAL AND PEDIATRIC HEALTH
Presenting Author: 
Debika Bhattacharya
Presenter Institution: 
University of California Los Angeles